Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

6.29
-0.5450-7.97%
Post-market: 6.380.0900+1.43%19:59 EDT
Volume:8.36M
Turnover:53.59M
Market Cap:365.69M
PE:-2.55
High:7.08
Open:6.81
Low:6.01
Close:6.84
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:45.54M
Volume Ratio:0.38
T/O Rate:18.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:1.49
PE(LYR):-2.78

Loading ...

Capricor Therapeutics, Inc. Expected to Post a Loss of 59 Cents a Share - Earnings Preview

Reuters
·
Aug 12

Capricor Therapeutics Updates Financial Calendar with Q2 Results Release, Conference Call and Webcast Scheduled

Reuters
·
Aug 10

Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13

THOMSON REUTERS
·
Aug 10

OTLK, HBAN, CORT, CAPR, GOSS Trending With Analysts

TIPRANKS
·
Aug 01

B. Riley Adjusts Capricor Therapeutics Price Target to $5 From $10, Maintains Neutral Rating

MT Newswires Live
·
Jul 31

Health ROUNDS-Experimental Drug Helps Advanced Cancer Patients Avoid Bladder Removal Surgery

Reuters
·
Jul 31

Capricor Therapeutics downgraded to Hold from Buy at JonesResearch

TIPRANKS
·
Jul 31

Health Rounds: Experimental Cell Therapy Slows Heart Failure Progression in Duchenne Muscular Dystrophy

Reuters
·
Jul 31

U.S. Stocks on the MOVE-Mastercard, Starbucks, Meta

Reuters
·
Jul 30

Capricor Therapeutics Hit 52-Week Low on Negative FDA Panel Vote

Dow Jones
·
Jul 30

Capricor: FDA committee voted evidence did not support Deramiocel effectiveness

TIPRANKS
·
Jul 30

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

THOMSON REUTERS
·
Jul 30

Capricor Therapeutics - Targets August 22, 2026 Pdufa Date for Deramiocel FDA Decision

THOMSON REUTERS
·
Jul 30

Capricor Therapeutics Inc : Maxim Group Cuts to Hold from Buy

THOMSON REUTERS
·
Jul 30

Capricor Therapeutics Inc. : Oppenheimer Cuts to Perform from Outperform

THOMSON REUTERS
·
Jul 30

Street View: Capricor in 'precarious Position' as Approval in Doubt

Reuters
·
Jul 30

HC Wainwright Downgrades Capricor Therapeutics to Neutral From Buy

MT Newswires Live
·
Jul 30

Capricor Therapeutics Cut to Neutral from Buy by HC Wainwright & Co.

Dow Jones
·
Jul 30

Capricor Therapeutics resumes trading, shares sink 55% to $2.99

TIPRANKS
·
Jul 30

Capricor Therapeutics Shares Down 52% Premarket After FDA Panel Votes Against Co's Duchenne Heart Disease Therapy

THOMSON REUTERS
·
Jul 30